1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Cancer Cachexia Therapeutics Market by Product and Geography - Forecast and Analysis 2019-2023

Cancer Cachexia Therapeutics Market by Product and Geography - Forecast and Analysis 2019-2023

  • October 2019
  • 148 pages
  • ID: 5824493
  • Format: PDF
  • By Infiniti Research Limited

Summary

Table of Contents

Global Cancer Cachexia Therapeutics Market: About this market
This cancer cachexia therapeutics market analysis considers sales from progestogens, corticosteroids, combination therapies, and other therapeutic products. Our study also finds the sales of cancer cachexia therapeutics in Asia, Europe, North America, and ROW. In 2018, the progestogens segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the effective and safest option for the palliative treatment of cancer cachexia will play a significant role in the progestogens segment to maintain its market position. Also, our global cancer cachexia therapeutics market report looks at factors such as high prevalence and incidence of cancer cachexia, strong pipeline landscape, and rising geriatric population. However, lack of approved therapies to treat cancer cachexia, side effects associated with corticosteroids, and stringent regulatory guidelines may hamper the growth of the cancer cachexia therapeutics industry over the forecast period.

Global Cancer Cachexia Therapeutics Market: Overview
High prevalence and incidence of cancer cachexia
Globally, the cancer burden is high, which can be attributed to population growth, poverty, infections, and unhealthy lifestyle habits, among others. The high prevalence and incidence of cancer are directly proportional to the number of cancer cachexia cases. The large patient cohort requires multiple physician visits and numerous medications for the treatment of cancer cachexia, which is consequently driving market growth. Cancer cachexia is a complex syndrome, which is characterized by muscle wasting, anorexia, fatigue, and anemia, leading to progressive functional damage, and is estimated to affect over half of all cancer patients. There is a huge cancer patient population in Asia, with China, India, and Japan being among the top five countries with the highest incidence of cancer. Thus, the high prevalence and incidence of the disease will lead to the expansion of the global cancer cachexia therapeutics market at a CAGR of almost 6% during the forecast period.
Rising preference for novel therapies
The lack of approved drugs for the treatment of cachexia in patients and administration of monotherapy with progestogens and corticosteroids have driven cancer patients and physicians to opt for alternative therapeutic approaches. Consequently, a combination of multiple medical and nutritional therapeutic interventions are gaining traction in the market. These therapeutics offer better safety and efficacy profiles. The increasing R&D by companies and the availability of novel drugs for the treatment of cancer cachexia facilitates their adoption among patients. This development is expected to have a positive impact on the overall market growth.

Competitive Landscape
With the presence of several major players, the global cancer cachexia therapeutics market is fragmented. This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading cancer cachexia therapeutics manufacturers, that include AbbVie Inc., ANI Pharmaceuticals Inc., Bristol-Myers Squibb Co., Fresenius SE & Co. KGaA, Hikma Pharmaceuticals Plc., Merck & Co. Inc., Mylan NV, Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.
Also, the cancer cachexia therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Hyperglycemia - Pipeline Review, H2 2019

Hyperglycemia - Pipeline Review, H2 2019

  • $ 2000
  • December 2019

Hyperglycemia - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Hyperglycemia - Pipeline Review, H2 2019, provides an overview of the Hyperglycemia (Metabolic ...

Corneal Neovascularization - Pipeline Review, H2 2019

Corneal Neovascularization - Pipeline Review, H2 2019

  • $ 2000
  • December 2019

Corneal Neovascularization - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Corneal Neovascularization - Pipeline Review, H2 2019, provides an overview of ...

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline Review, H2 2019

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline Review, H2 2019

  • $ 2000
  • December 2019

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ...


ref:plp2019

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on